Kinvestor Network

Five Stocks to Consider When Investing in the Diabetes Market

Diabetes is a chronic disease that impairs our body’s ability to produce insulin or use it to create energy from the food we eat. The inability to make or use insulin results in increased glucose levels in the blood or hyperglycaemia. Unfortunately, diabetes is a health condition that affects millions of people around the world.

NuGen M.D. Launches PetJet™ Providing Needle-Free Injections for Domesticated Pets

Reducing Fear and Risk of Injury for Pet Owners and their Furry Loved Ones

TORONTO, Ontario – June 22, 2022 – NuGen Medical Devices Inc. (TSXV: NGMD) (“NuGen” or the “Company”), a leader in needle-free drug delivery, is pleased to announce that it will be launching a needle-free injection device specifically designed for domesticated household pets.

The PetJetTM will allow pet owners and veterinarians to safely and quickly inject various types of medication without the fear of hurting their pets with a traditional hypodermic needle.

Seventy percent of U.S. households, or about 90.5 million families, own a pet, according to the 2021-2022 National Pet Owners Survey conducted by the American Pet Products Association (APPA). This is up from 56 percent of U.S. households in 1988, the first year the survey was conducted, and 67 percent in 2019.

As in humans, dogs and cats with diabetes often require lifelong treatment which may include daily injections of insulin. According to the American Veterinary Medical Association (AVMA), diabetes can occur in cats and dogs of any age, although it is often diagnosed later in the animal’s life and, if not treated with proper insulin and feeding schedules, may cause long-term harm to the pet.

Michael Wright, CEO of NuGen M.D. states, “Our needle-free solution offers more than just improved health care opportunities in humans, but brings a much-needed solution for the millions of domesticated pets suffering from chronic illness in North America. While diabetes is a growing concern and cost in humans, it is also in pets. Our device can be used 5,000 times across many medications for use in pets. It can be devastating for a loving pet owner to jab their pets daily or weekly in order to administer lifesaving medication. However, with PetJet™, these pet owners will be able to deliver the medication without the negative associations of hypodermic needles.”

In 2016, the State of Pet Health Report found that diabetes is on the rise in both dogs and cats, with diagnoses increasing nearly 80% in dogs and 18% in cats over a 10-year period. Currently, about one in every 300 dogs and one in 230 cats are diagnosed with diabetes during their lifetimes, although research suggests that many cases still go undiagnosed.

Like the NuGen M.D. needle-free injection system, also known as InsuJet™, which is a self-administered needle-free injection system approved by Health Canada and in over 40 other countries globally, the PetJet™ can be safely used 5,000 times without the risk of needle-stick injury or cross-contamination as well as eliminating the waste management of sharps (used needles), making it easier for owners to provide at-home care to their pets.

For veterinarians, the PetJet™ presents an alternative to hypodermic needles that present real dangers like needlestick injuries, which can be permanently damaging, life changing, and are becoming more of a concern among veterinary medicine professionals. The Veterinary Medicines Directorate (VMD) has reported several cases of long-term issues from veterinary needlestick injury including prolonged pain, inflammation, and restrictions to mobility.

About NuGen Medical Devices

NuGen Medical Devices’ principal business is the development and commercialization of innovative needle-free injection devices and systems for the administration of subcutaneous medication.

It is developing products using needle-free drug delivery technology in several important fields including, but not limited to, anaphylaxis, diabetes, severe migraine, erectile dysfunction, chronic anemia, neutropenia, autoimmune rheumatoid arthritis, growth and fertility hormone, psoriasis as well as DNA and conventional/pediatric vaccines.

For More Information visit: www.nugenmd.com
Twitter: @NuGenMD
LinkedIn: https://www.linkedin.com/company/nugenmd/

For further information, please contact:
Michael Wright
President and CEO
NuGen Medical Devices Inc.
[email protected]

Investor Relations Contact:
Kin Communications Inc.
[email protected].com
(604) 684-6730

Twitter: @KinComm

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

This news release contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements.  Forward looking statements in this press release include the Company’s 2022 objectives of securing additional distribution and sales agreements, making submissions for regulatory approvals and capitalizing on additional market opportunities. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.

NuGen Announces Results of its Annual and Special Meeting and Approval of Amendments to Stock Option Plan

Toronto, Ontario – June 17, 2022 – NuGen Medical Devices Inc. (TSXV: NGMD) (the “Company”) is pleased to announce that all matters  submitted  to  shareholders  for  approval as set out in detail in the Company’s management information circular (“Circular”) dated May 17, 2022 were approved at the annual and special meeting of the shareholders of the Company held on June 17, 2022 (the  “Meeting”).  At the Meeting, KPMG LLP was re-appointed as auditor of the Company, and the incumbent members of the board of directors, being Michael Wright, John Leombruno, Derek Lindsay, Karen Dunlap and William Cleman were re-elected.

The Company is also pleased to announce that its proposal to amend the terms of the stock option plan of the Company (the “Plan”) as a result of certain revisions made to TSX Venture Exchange Policy 4.4 – Security Based Compensation (“Policy 4.4”), which came into effect on November 24, 2021, was approved at the Meeting. For more information on the changes to Policy 4.4, please see the TSXV Bulletin re Policy 4.4 – Security Based Compensation dated November 24, 2021. The Plan was conditionally approved by the TSX Venture Exchange on May 26, 2022.

About NuGen Medical Devices:

NuGen is an emerging specialty medical device company focused on developing and commercializing novel drug delivery technologies. NuGen’s principal business is the development and commercialization of innovative needle-free injection devices and systems for the administration of subcutaneous medication. It is developing products using needle-free drug delivery technology in several important fields including, but not limited to, anaphylaxis, diabetes, severe migraine, erectile dysfunction, chronic anemia, neutropenia, autoimmune rheumatoid arthritis, growth and fertility hormone, psoriasis as well as DNA and conventional/pediatric vaccines.

For further information, please visit:

Website: www.nugenmd.com

Twitter: @NuGenMD

LinkedIn: https://www.linkedin.com/company/nugenmd/

For further information, please contact:

Michael Wright
President and CEO
NuGen Medical Devices Inc.
[email protected]

Investor Relations Contact:

 Kin Communications Inc.
[email protected]
(604) 684-6730

Notice Regarding Forward-Looking Information:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.